To evaluate the impact of herpes zoster vaccine on the incidence of herpes zoster and survival in lung cancer patients, and to explore its preventive effect and safety.
1.Male or female patients >=18 years of age; 2.Histological diagnosis of NSCLC, including both non-small cell lung cancer and small cell lung cancer, regardless of whether they are in the early, locally advanced stage or advanced stage, and regardless of whether they have received surgery, radiotherapy, chemotherapy or other treatments; 3. Never received herpes zoster vaccine
Patients having other factors that preventing researchers from enrollment them.
Lung cancer patients can receive or not receive the herpes zoster vaccine
Cohort
Prospective
herpes zoster vaccine
Biological/VaccineReceive the herpes zoster vaccine; Do not receive the herpes zoster vaccine
The incidence of herpes zoster at 12 months
During the 12-month follow-up period, the incidence of herpes zoster in lung cancer patients was evaluated through regular clinical examinations, imaging tests, and laboratory tests.
Incidence of herpes zoster
The proportion of lung cancer patients who developed herpes zoster during the study period.
Survival rate
The survival rate of lung cancer patients within a specific time period (such as 1 year, 2 years, or 5 years).
Lung cancer-related complications
Severity of herpes zoster and incidence of complications (e.g., postherpetic neuralgia)
Length of hospital stay
Record the number of days of hospitalization for patients hospitalized due to herpes zoster
Hospitalization rate
The proportion of patients hospitalized due to herpes zoster or other related complications.
Immune response
The immune response (such as antibody levels) of patients after vaccination is evaluated through serological testing.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
